论文部分内容阅读
美国新奥尔良消息:一项对治疗近视最有效的尖端技术开始研究。所谓epikeratophaki或EPI,是将供者角膜移植体缝合于眼表面,形成由活组织构成的永久性晶状体。路易斯安那州立大学医学校Herbers Kaufman和Mar-guerite McDonald在近七年中研制了此项新技术。最初设想是作为治疗出生患白内障或双眼视力有明显差别的婴幼儿的一种方法。两年来,EPI已成为该院医生和加利福尼亚圣安那美国眼科医学会(AMO)医生联合研究的课题。
New Orleans, United States: One of the most effective cutting-edge technologies for the treatment of myopia began to study. The so-called epikeratophaki or EPI, the donor corneal graft sutured to the ocular surface, the formation of permanent tissue composed of living tissue. Herbers Kaufman and Mar-Guerite McDonald of Louisiana State University Medical School developed the new technology in nearly seven years. Initially conceived as a way of treating infants and toddlers who were born with cataract or who had significant differences in binocular vision. For two years, EPI has become the subject of a joint study between physicians at the hospital and physicians at the American Academy of Ophthalmology (AMO) in San Ana, California.